Skip to main content

Table 4 Comparison between patients with one flare or less vs. patients with more than a flare

From: Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study

 Patients with one flare or less
(n = 5)
Patients with more than a flare
(n = 8)
p-value
Age, mean (SD), years40.8 ± 15.752.9 ± 12.5NS
Female, n (%)3 (60%)6 (75%)NS
Disease duration, mean (SD), years12.4 ± 8.710.9 ± 10.4NS
TCZ exposure before tapering, months (SD)16.4 ± 8.820.4 ± 5.7NS
Remission achievement delay, months (SD)3 ± 2.42 ± 2.8NS
Remission duration, months (SD)5.6 ± 2.88.8 ± 7.5NS
RF positive, n (%)0 (0%)7 (87.5%)0.004
ACPA positive, n (%)0 (0%)7 (87.5%)0.004
Erosive status, n (%)3 (60%)7(87.5%)NS
Previous number of sDMARDs1.8 ± 0.82.4 ± 1NS
Previous number of bDMARDs1.6 ± 1.11.75 ± 1.3NS
Swollen joint count00.125 ± 0.3NS
Tender joint count2.4 ± 4.33.6 ± 2.97NS
Hyperhemia at Doppler0 (0%)(37.5%)NS
Number of patients with active synovitis3 (60%)4(50%)NS
Number of active synovitis
 Hands311NS
 Feet23NS
Concomitant therapy
 MTX, n (%)3 (60%)3 (37.5%)NS
 LEF, n (%)1 (20%)2 (25%)NS
Flare, mean (SD)0.6 ± 0.52.13 ± 0.350.001
  1. SD standard deviation, n number, TCZ tocilizumab, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, MTX methotrexate, LEF leflunomide, NS non-significant